CSTL Castle Biosciences

Castle Biosciences Hosts Groundbreaking Ceremony at Site of New Corporate Headquarters in Friendswood, Texas

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it will hold a groundbreaking ceremony to celebrate the recent construction start of its new corporate campus and office building. The ceremony will take place on Oct. 22, 2024, at 10:00 a.m. Central time at the project site, located at 1500 West Parkwood Avenue in Friendswood, Texas. Local, state and national elected officials are expected to attend.

This press release features multimedia. View the full release here:

Castle Biosciences' New Corporate Headquarters in Friendswood, Texas (Photo: Business Wire)

Castle Biosciences' New Corporate Headquarters in Friendswood, Texas (Photo: Business Wire)

“We are thrilled to have broken ground on our new corporate headquarters in Friendswood, a place we have proudly called home since our inception in 2008,” said Derek Maetzold, president and chief executive officer of Castle Biosciences. “The new, state-of-the-art facility reflects our commitment to our people and the community and is designed to foster a collaborative environment that nurtures our employees, facilitates our future growth and supports our mission of improving patient care.”

The Company’s four-story headquarters building will encompass approximately 80,000 square feet of Class A office space. Unique amenities include a covered rooftop deck providing outdoor collaborative space and a corporate fitness center planned for the ground level. The 23-acre wooded campus has been thoughtfully designed with walking trails and covered pavilions to allow nature respites throughout the workday.

“It was always important to Castle that we design the new headquarters with an employee-centric focus,” said Jason Tramonte, Jr., AIA, IIDA, architect and owner of Tramonte Design Studio, the architecture and interior design firm on the project. “Each detail — from the big-picture campus plan down to the individual office spaces — was carefully planned to foster an environment conducive to a myriad of work styles, whether collaborative or private, indoor or outdoor, or any combination thereof.”

In addition to their Friendswood headquarters, Castle operates clinical laboratories in Phoenix and Pittsburgh.

About Castle Biosciences

Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company improving health through innovative tests that guide patient care. The Company aims to transform disease management by keeping people first: patients, clinicians, employees and investors.

Castle’s current portfolio consists of tests for skin cancers, Barrett’s esophagus, mental health conditions and uveal melanoma. Additionally, the Company has active research and development programs for tests in other diseases with high clinical need, including its test in development to help guide systemic therapy selection for patients with moderate-to-severe atopic dermatitis, psoriasis and related conditions. To learn more, please visit and connect with us on , , and .

EN
02/10/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Castle Biosciences

 PRESS RELEASE

Castle Biosciences to Present Data at SSO 2026 on DecisionDx®-Melanoma...

Castle Biosciences to Present Data at SSO 2026 on DecisionDx®-Melanoma’s i31-SLNB, Identifying T1b–T2a Melanoma Patients Who May Safely Avoid SLNB FRIENDSWOOD, Texas, March 04, 2026 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that new data evaluating DecisionDx-Melanoma’s i31-SLNB test result for prediction of sentinel lymph node (SLN) positivity will be presented at the Society of Surgical Oncology (SSO) 2026 Annual Meeting, being held March 5-7 in Phoenix. “The initial reports ...

 PRESS RELEASE

Castle Biosciences Announces Grand Opening of New Corporate Headquarte...

Castle Biosciences Announces Grand Opening of New Corporate Headquarters in Friendswood, Texas FRIENDSWOOD, Texas, March 03, 2026 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it will host a grand opening celebration for its new corporate headquarters on Tuesday, March 24, 2026, at 3:00 p.m. Central time. The event will take place at the Company’s new campus located at 1500 West Parkwood Avenue in Friendswood, Texas, and will bring together employees, community partners and oth...

 PRESS RELEASE

Castle Biosciences Reports Fourth Quarter and Full–Year 2025 Results

Castle Biosciences Reports Fourth Quarter and Full–Year 2025 Results 2025 total test reports for our core revenue drivers (DecisionDx®-Melanoma, TissueCypher®) increased 37% over 2024 Exceeded 2025 guidance with full-year revenue of $344 million Conference call and webcast today at 4:30 p.m. ET FRIENDSWOOD, Texas, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced its financial results for the fourth quarter and year ended Dec. 31, 2025.“We closed out an outstanding year...

 PRESS RELEASE

Prospective Validation Study in JAAD Demonstrates Castle Biosciences’ ...

Prospective Validation Study in JAAD Demonstrates Castle Biosciences’ AdvanceAD-Tx™ Test Identifies Patients More Likely to Achieve Faster and Deeper Responses with JAK Inhibitor Therapy in Moderate-to-Severe Atopic Dermatitis Study data show that AdvanceAD-Tx can stratify patients by molecular profile identifying those more likely to achieve near-clear skin (EASI-90), faster time to response and meaningful patient-reported benefits when treated with JAK inhibitor therapy compared to a Th2-targeted therapy FRIENDSWOOD, Texas, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (N...

 PRESS RELEASE

Castle Biosciences to Release Fourth Quarter and Full-Year 2025 Financ...

Castle Biosciences to Release Fourth Quarter and Full-Year 2025 Financial Results and Host Conference Call on Thursday, Feb. 26, 2026 FRIENDSWOOD, Texas, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it will release its financial results for the fourth quarter and year ended Dec. 31, 2025, after the close of market on Thursday, Feb. 26, 2026. Company management will host a conference call and webcast to discuss its financial results at 4:30 p.m. Eastern time on t...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch